Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea · Delayed Price · Currency is KRW 5,280.00
-80.00 (-1.49%)
Last updated: Feb 26, 2026, 2:10 PM KST
Bukwang Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 9,736 | -2,641 | -31,330 | -2,475 | -916.62 | -7,203 |
Depreciation & Amortization | 5,223 | 4,106 | 4,292 | 5,117 | 4,843 | 6,158 |
Loss (Gain) From Sale of Assets | -357.18 | -53.75 | -30.64 | -52.25 | -220.05 | -54.25 |
Asset Writedown & Restructuring Costs | 3,586 | 9,585 | - | - | - | 3,539 |
Loss (Gain) From Sale of Investments | 3,602 | -738.9 | 564.4 | 567.47 | -90.53 | 3,297 |
Loss (Gain) on Equity Investments | 782.91 | -343.13 | 1,501 | -58.57 | 1,361 | 2,838 |
Stock-Based Compensation | -3.53 | -3.53 | 147.49 | 44.33 | 3.41 | 3,226 |
Provision & Write-off of Bad Debts | -72.19 | -554.54 | -4,897 | 2,902 | 1,694 | 1,264 |
Other Operating Activities | 4,584 | 379.98 | -3,373 | 3,261 | 917.18 | -3,028 |
Change in Accounts Receivable | -4,053 | 12,933 | 57,117 | -423.74 | 11,554 | 6,663 |
Change in Inventory | -5,917 | 14,296 | -18,388 | 208.43 | 12,182 | -7,814 |
Change in Accounts Payable | 6,201 | 2,432 | -14,160 | 9,154 | -2,735 | -1,102 |
Change in Other Net Operating Assets | -748.22 | -5,035 | -806.65 | -1,782 | -2,066 | -7,060 |
Operating Cash Flow | 22,563 | 34,362 | -9,362 | 16,461 | 26,525 | 723.17 |
Operating Cash Flow Growth | -44.21% | - | - | -37.94% | 3567.88% | - |
Capital Expenditures | -5,573 | -1,938 | -2,835 | -4,298 | -785.05 | -1,917 |
Sale of Property, Plant & Equipment | 797.46 | 45.52 | 142.2 | 71.27 | 388.45 | 18,215 |
Divestitures | -11,552 | 369.75 | 238.89 | - | - | - |
Sale (Purchase) of Intangibles | -4,025 | -629.25 | 267.3 | -692.11 | -4.47 | -36.93 |
Investment in Securities | -174,894 | -25,575 | -152.85 | 1,588 | 5,150 | -3,213 |
Other Investing Activities | 0 | 0 | 20 | 180 | -0 | 0 |
Investing Cash Flow | -195,247 | -27,727 | -2,319 | -3,151 | 4,749 | 13,048 |
Short-Term Debt Issued | - | 10,000 | - | 10,000 | - | 96,300 |
Long-Term Debt Issued | - | - | 80,000 | - | - | - |
Total Debt Issued | - | 10,000 | 80,000 | 10,000 | - | 96,300 |
Short-Term Debt Repaid | - | -10,000 | - | -10,000 | -20,000 | -76,300 |
Long-Term Debt Repaid | - | -63,602 | -447.86 | -433.92 | -452.42 | -443.28 |
Total Debt Repaid | -487.75 | -73,602 | -447.86 | -10,434 | -20,452 | -76,743 |
Net Debt Issued (Repaid) | -487.75 | -63,602 | 79,552 | -433.92 | -20,452 | 19,557 |
Issuance of Common Stock | 88,158 | - | - | 100 | - | - |
Repurchase of Common Stock | - | - | - | - | -516.19 | -25,112 |
Dividends Paid | - | - | - | -6,845 | -6,225 | -12,190 |
Other Financing Activities | -3,549 | -4,049 | -2,714 | -469.66 | -290.94 | 45,978 |
Financing Cash Flow | 84,121 | -67,651 | 76,839 | -10,398 | -27,485 | 28,232 |
Foreign Exchange Rate Adjustments | 490.55 | -120.02 | 552.82 | -172.98 | -303.37 | -297.75 |
Net Cash Flow | -88,073 | -61,136 | 65,710 | 2,740 | 3,486 | 41,706 |
Free Cash Flow | 16,990 | 32,424 | -12,196 | 12,163 | 25,740 | -1,194 |
Free Cash Flow Growth | -56.31% | - | - | -52.74% | - | - |
Free Cash Flow Margin | 9.21% | 20.25% | -9.69% | 6.37% | 14.11% | -0.70% |
Free Cash Flow Per Share | 228.56 | 473.65 | -178.17 | 177.69 | 375.98 | -17.40 |
Cash Interest Paid | 3,532 | 4,032 | 1,139 | 147.12 | 290.94 | 947.14 |
Cash Income Tax Paid | - | 1,588 | 900.4 | 4,116 | 8,933 | 9,093 |
Levered Free Cash Flow | -6,562 | -34,262 | 59,149 | 9,285 | 25,241 | 1,316 |
Unlevered Free Cash Flow | -2,506 | -30,206 | 61,529 | 10,385 | 26,121 | 2,263 |
Change in Working Capital | -4,518 | 24,626 | 23,763 | 7,156 | 18,934 | -9,313 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.